European guideline (EuroGuiDerm) on atopic eczema : part I - systemic therapy
Wollenberg, A. (Universitair Ziekenhuis Brussel)
Kinberger, M. (Charité - Universitätsmedizin Berlin)
Arents, B. (European Federation of Allergy and Airways Diseases Patients' Associations)
Aszodi, N. (LMU Munich)
Avila Valle, G. (Charité - Universitätsmedizin Berlin)
Barbarot, Sebastien (Nantes Université)
Bieber, T. (University Hospital of Bonn)
Brough, H.A. (King's College London)
Calzavara Pinton, P. (University of Brescia)
Christen-Zäch, S. (Lausanne University Hospital)
Deleuran, M. (Aarhus University Hospital (Aarhus, Dinamarca))
Dittmann, M. (Charité - Universitätsmedizin Berlin)
Dressler, C. (Charité - Universitätsmedizin Berlin)
Fink-Wagner, A.H. (Global Allergy and Airways Diseases Patient Platform)
Fosse, N. (University Hospital Basel)
Gáspár, K. (University of Debrecen)
Gerbens, L. (Amsterdam UMC)
Gieler, U. (University of Giessen)
Girolomoni, Giampiero (University of Verona)
Gregoriou, S. (National and Kapodistrian University of Athens)
Mortz, C. G. (University of Southern Denmark)
Nast, A. (Charité - Universitätsmedizin Berlin)
Nygaard, U. (Aarhus University Hospital (Aarhus, Dinamarca))
Redding, M. (Eczema Outreach Support)
Rehbinder, E.M. (Oslo University Hospital (Oslo, Noruega))
Ring, J. (Technical University Munich)
Rossi, M. (Spedali Civili Hospital Brescia)
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau)
Simon, D. (University of Bern)
Szalai, Z.Z. (Heim Pál National Children's Institute Budapest)
Szepietowski, J.C. (Wroclaw Medical University)
Torrelo, A. (Hospital Infantil Universitario Niño Jesús (Madrid))
Werfel, T. (Hannover Medical School)
Flohr, C. (Guy's & St Thomas' NHS Foundation Trust)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Atopic dermatitis ; Atopic eczema
Published in:	Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 9 (september 2022) , p. 1409-1431, ISSN 1468-3083

DOI: 10.1111/jdv.18345
PMID: 35980214

23 p, 887.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles